TGFB1 and cancer: The enhanced secretion of these proteolytic enzymes is believed to cleave various ECM components such as decorin, which covalently binds to TGF-β and consequently prevents the latter from binding to the TGF-β receptor in adjacent cancer cells and initiating EMT 44.